FBRX
Forte Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
Significant Net Income Decline
Dark Cloud Cover
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FBRX
Forte Biosciences, Inc.
A biotech company that develops and commercializes innovative skin and hair care products
Life Science Tools and Services
--
04/13/2017
NASDAQ Stock Exchange
14
12-31
Common stock
3060 Pegasus Park Drive, Building 6, Dallas, Texas 75247
--
Forte Biosciences, Inc., is a clinical-stage dermatological company dedicated to the development of living biotherapies FB-401 for the treatment of inflammatory skin diseases. FB-401 has completed phase 1/2 a testing in adults and children (3 years and older) with atopic dermatitis. There is a substantial demand for safe and effective therapies, especially for patients with pediatric atopic dermatitis. Forte plans to advance FB-401 into Phase 2 clinical trials in the mid 2020s.
Company Financials
EPS
FBRX has released its 2025 Q3 earnings. EPS was reported at -0.99, versus the expected -1.07, beating expectations. The chart below visualizes how FBRX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
